CareDx reports FY2023 revenue $280.3M, exceeding guidance; Q4 net loss includes $96.3M patent accrual

CareDx, Inc.

2023-FY EPS reported -$3.54 revenue$280,324,000

Full-year revenue $280.3M, down 13% YoY; Testing Services revenue $209.7M, down 20%.
Q4 revenue $65.6M, down 20% YoY; net loss $118.1M, including $96.3M patent infringement accrual.
Non-GAAP net loss per share Q4 $0.17; full-year adjusted EBITDA loss $38.0M.
Cash and marketable securities $235.4M; repurchased 2.9M shares for $27.5M in 2023.
Seeking judicial review of January 2024 jury verdict on patent ‘544; Medicare coverage added for HeartCare and AlloSure Lung.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.